Stock Market Today: Dow Leads as UnitedHealth Stock Pops
UnitedHealth was the best Dow Jones stock Monday on reports that Medicare Advantage payments could rise in 2026.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
Stocks were mixed to start the first full trading week of 2025. While the Dow Jones Industrial Average outperformed on strength in UnitedHealth Group (UNH) shares, the Nasdaq Composite fell as tech stocks continued to decline.
At the close, the Dow was up 0.9% to 42,297 as UnitedHealth surged 3.9% after a release from the Centers for Medicare & Medicaid Services (CMS) suggested Medicare Advantage payments could potentially increase by more than 4% next year.
At roughly $545 a share, UnitedHealth has the greatest influence on the price-weighted Dow.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Johnson & Johnson (JNJ) was also one of the top-performing Dow Jones stocks today, adding 1.7%, on news the pharmaceutical giant is buying neuroscience specialist Intra-Cellular Therapies (ITCI, +34.1%) for $14.6 billion in cash.
Jeff Jonas, portfolio manager at Gabelli Funds, is cautious on the deal, mostly due to antitrust concerns. "JNJ has a late-stage Depression drug and has always been a leader in Schizophrenia," he wrote in emailed commentary. "Yes, it's a different mechanism of action but still a lot of overlap. Their timing to close the deal of 'later this year' seems to incorporate a tough review, even under the new administration."
Nvidia drops on updated AI chip rules
The S&P 500 managed to add 0.2% to end at 5,836, while the Nasdaq slumped 0.4% to 19,088 on continued weakness in the tech sector.
Nvidia (NVDA) was one of the more notable decliners, sliding 2.0% after the Biden administration released new rules on how artificial intelligence (AI) chips and models can be shared with other countries, including issuing caps on the number of AI chips that can be exported to specific nations.
U.S. allies such as Britain and Canada are not subject to the restrictions while countries such as China and Russia will continue to face full bans on AI chip purchases.
In a statement, Nvidia said the new rules are a "sweeping overreach" that threaten "to derail innovation and economic growth worldwide."
Palantir keeps sliding
Palantir Technologies (PLTR), an AI software company, also sold off today, ending the session down 3.4%. PLTR was one of the hottest stocks of 2024 – more than quadrupling in value – but has shed 14% so far in 2025.
Morgan Stanley analyst Sanjit Singh recently initiated coverage on the tech stock with an Underweight (Sell) rating and a $60 price target, nearly 7% below where shares are currently trading.
"In the past 18 months or so, Palantir has driven better-than-expected U.S. commercial traction, U.S. government deal momentum, and operating expense discipline," Singh wrote in a January 6 note. This is now well-reflected in the share price, he adds.
Singh admits that the incoming Trump administration could create tailwinds for PLTR, but for now, the stock is "trading too far ahead of the company's intrinsic value to justify a rating upgrade."
Inflation data could spark more volatility
"The recent weakness in equity and bond markets, despite an encouraging payroll report, underscores a heightened sensitivity to inflation expectations and a prevailing pessimistic sentiment," says Mark Hackett, chief market strategist at Nationwide.
This "heightened sensitivity" could create more volatility for stocks following the release of key inflation data this week. Specifically, the December Producer Price Index (PPI) is set for release ahead of Tuesday's open and the December Consumer Price Index (CPI) is due out Wednesday morning.
Bank earnings will also start to roll in on Wednesday, with JPMorgan Chase (JPM) and Goldman Sachs (GS) among those reporting. You can follow all our earnings coverage on Kiplinger's earnings season live blog.
Related content
- Kiplinger's Economic Calendar for This Week
- Earnings Calendar and Analysis for This Week
- When Is the Next Jobs Report?
-
The New Reality for EntertainmentThe Kiplinger Letter The entertainment industry is shifting as movie and TV companies face fierce competition, fight for attention and cope with artificial intelligence.
-
Stocks Sink With Alphabet, Bitcoin: Stock Market TodayA dismal round of jobs data did little to lift sentiment on Thursday.
-
Betting on Super Bowl 2026? New IRS Tax Changes Could Cost YouTaxable Income When Super Bowl LX hype fades, some fans may be surprised to learn that sports betting tax rules have shifted.
-
Stocks Sink With Alphabet, Bitcoin: Stock Market Today
A dismal round of jobs data did little to lift sentiment on Thursday.
-
The 4 Estate Planning Documents Every High-Net-Worth Family Needs (Not Just a Will)The key to successful estate planning for HNW families isn't just drafting these four documents, but ensuring they're current and immediately accessible.
-
Love and Legacy: What Couples Rarely Talk About (But Should)Couples who talk openly about finances, including estate planning, are more likely to head into retirement joyfully. How can you get the conversation going?
-
How to Get the Fair Value for Your Shares When You Are in the Minority Vote on a Sale of Substantially All Corporate AssetsWhen a sale of substantially all corporate assets is approved by majority vote, shareholders on the losing side of the vote should understand their rights.
-
Dow Leads in Mixed Session on Amgen Earnings: Stock Market TodayThe rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.
-
How to Add a Pet Trust to Your Estate Plan: Don't Leave Your Best Friend to ChanceAdding a pet trust to your estate plan can ensure your pets are properly looked after when you're no longer able to care for them. This is how to go about it.
-
Want to Avoid Leaving Chaos in Your Wake? Don't Leave Behind an Outdated Estate PlanAn outdated or incomplete estate plan could cause confusion for those handling your affairs at a difficult time. This guide highlights what to update and when.
-
I'm a Financial Adviser: This Is Why I Became an Advocate for Fee-Only Financial AdviceCan financial advisers who earn commissions on product sales give clients the best advice? For one professional, changing track was the clear choice.
